Bronchiectasis, part 2: Management
Abstract
Systemic antibiotics are the mainstay of the management of acute exacerbations of bronchiectasis. Antibiotic selection should include coverage for Streptococcus pneumoniae and Haemophilus influenzae; particular attention also should be paid to the presence of Staphylococcus aureus and Pseudomonas species. The duration of antibiotic therapy is not well-established, but most clinicians recommend a prolonged course, often longer than 3 weeks. There is some evidence that long-term low-dose macrolide therapy can reduce the incidence of acute exacerbations and decrease sputum production. There also may be a role for the use of inhaled antibiotics. Airway clearance strategies, such as chest percussion and postural drainage, are clearly useful in patients with cystic fibrosis and may be useful in other patients with bronchiectasis. Surgical resection can be considered if a patient has localized disease that is refractory to medical management or if he/she is unwilling to undergo long-term medical therapy.
Similar articles
-
[Chinese experts consensus statement: diagnosis and treatment of cystic fibrosis (2023)].Zhonghua Jie He He Hu Xi Za Zhi. 2023 Apr 12;46(4):352-372. doi: 10.3760/cma.j.cn112147-20221214-00971. Zhonghua Jie He He Hu Xi Za Zhi. 2023. PMID: 36990700 Chinese.
-
Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis.Lancet Respir Med. 2019 Oct;7(10):845-854. doi: 10.1016/S2213-2600(19)30191-2. Epub 2019 Aug 9. Lancet Respir Med. 2019. PMID: 31405828
-
The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial.Lancet Respir Med. 2014 Dec;2(12):988-96. doi: 10.1016/S2213-2600(14)70213-9. Epub 2014 Oct 14. Lancet Respir Med. 2014. PMID: 25458200 Clinical Trial.
-
Mucociliary clearance techniques for treating non-cystic fibrosis bronchiectasis: Is there evidence?Int J Immunopathol Pharmacol. 2015 Jun;28(2):150-9. doi: 10.1177/0394632015584724. Epub 2015 Jun 15. Int J Immunopathol Pharmacol. 2015. PMID: 26078380 Review.
-
Inhaled antibiotics: A promising drug delivery strategies for efficient treatment of lower respiratory tract infections (LRTIs) associated with antibiotic resistant biofilm-dwelling and intracellular bacterial pathogens.Respir Med. 2024 Jun;227:107661. doi: 10.1016/j.rmed.2024.107661. Epub 2024 May 8. Respir Med. 2024. PMID: 38729529 Review.
References
-
- Martinez-Garcia MA, Perpina-Tordera N, Roman-Sanchez P, et al. Quality-of-life determinants in patients with clinically stable bronchiectasis. Chest. 2005;128:739–745. - PubMed
-
- Tsang KW, Chan WM, Ho PL, et al. A comparative study on the efficacy of levofloxacin and ceftazadime in acute exacerbation of bronchiectasis. Eur Respir J. 1999;14:1206–1209. - PubMed
-
- Evans DJ, Bara AI, Greenstone M. Prolonged antibiotics for purulent bronchiectasis in children and adults. Cochrane Database of Systematic Reviews. 2007;2:1–31. - PubMed
-
- Tsang KW, Ho PL, Chan KN, et al. A pilot study of low-dose erythromycin in bronchiectasis. Eur Respir J. 1999;13:361–364. - PubMed
-
- Cymbala AA, Edmonds LC, Bauer MA, et al. The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis. Treat Respir Med. 2005;4:117–122. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources